Comparison of the efficacy of TPO receptor agonist combined with rhTPO in platelet reconstruction after autologous hematopoietic stem cell transplantation for lymphatic tumor

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059894

Enrollment

Unknown

Registered

2022-05-13

Start date

2022-04-29

Completion date

Unknown

Last updated

2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

platelet reconstruction after autologous hematopoietic stem cell transplantation for lymphatic tumor

Interventions

H+TPO:Haitripopa+rhTPO

TPO:rhTPO

H:Haitripopa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with various types of lymphoma clearly diagnosed by bone marrow puncture or pathological examination; 2. The conditions of autologous hematopoietic stem cell transplantation were met and autologous stem cells were successfully transfused; 3. Informed consent signed by the applicant or the guardian.

Exclusion criteria

Exclusion criteria: 1. Contraindications of autologous hematopoietic stem cell transplantation; 2. Other malignant tumors; 3. The presence of immune system diseases; 4. Serious heart, liver, and kidney damage.

Design outcomes

Primary

Measure	Time frame
Hematopoietic reconstruction time;	—

Secondary

Measure	Time frame
The total number of platelets transfused during transplantation;	—

Countries

China

Contacts

Public ContactLiu Yao

Cancer Hospital Affiliated to Chongqing University

liuyao77@cqu.edu.cn+86 13228684685

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026